Altor signs a definitive agreement to sell PaloDEx to Danaher

Altor, a leading Nordic buy-out fund, today announced that it has signed a definitive agreement to sell PaloDEx to Danaher Corporation. Altor acquired the dental imaging assets from GE as a carve-out of non-core assets in September 2005 and formed a leading dental imaging company named PaloDEx.

Jaakko Kivinen, Partner of Altor Equity Partners, commented: “During Altor’s ownership, the objective has been to establish an independent company that can accelerate growth and improve operational efficiency of the dental imaging assets that were non-core operations for GE. As a result of the hard work of the management team and consistent execution of the operational agenda, PaloDEx has grown faster than the market with increasing profitability and improved working capital efficiency during our ownership.”

“To help achieve these results, we recruited a high quality, internationally experienced board and management team with strong leadership to execute on the ambitious operational plan, in line with Altor’s investment strategy of building lasting value in partnership with management. We are delighted that PaloDEx’s management team, led by Henrik Roos and Jyrki Perttunen, have delivered on that plan. This has been a very successful investment for us.”

“During our ownership, PaloDEx accelerated the pace of its product launches with several attractive and innovative products and revitalized the customer service driven strategy”, comments Fredrik Strömholm, Partner of Altor Equity Partners. “There is strong industrial logic behind the acquisition by Danaher, as a leading dental company in the world seeking to strengthen their dental imaging operations. The development of PaloDEx under Altor’s ownership is evidence of Altor’s capability of building non-core operations into attractive, globally leading companies in their field.”

“The transaction further contributes to PaloDEx’s strengths. We believe Danaher will be a great owner for PaloDEx, and as a key part of Danaher’s Dental Platform, PaloDEx will be able to expand its potential in the increasingly dynamic dental industry”, comments Henrik Roos, CEO of PaloDEx.

Posted in:

Tags:

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Danaher. (2019, June 24). Altor signs a definitive agreement to sell PaloDEx to Danaher. News-Medical. Retrieved on April 23, 2024 from https://www.news-medical.net/news/20091013/Altor-signs-a-definitive-agreement-to-sell-PaloDEx-to-Danaher.aspx.

  • MLA

    Danaher. "Altor signs a definitive agreement to sell PaloDEx to Danaher". News-Medical. 23 April 2024. <https://www.news-medical.net/news/20091013/Altor-signs-a-definitive-agreement-to-sell-PaloDEx-to-Danaher.aspx>.

  • Chicago

    Danaher. "Altor signs a definitive agreement to sell PaloDEx to Danaher". News-Medical. https://www.news-medical.net/news/20091013/Altor-signs-a-definitive-agreement-to-sell-PaloDEx-to-Danaher.aspx. (accessed April 23, 2024).

  • Harvard

    Danaher. 2019. Altor signs a definitive agreement to sell PaloDEx to Danaher. News-Medical, viewed 23 April 2024, https://www.news-medical.net/news/20091013/Altor-signs-a-definitive-agreement-to-sell-PaloDEx-to-Danaher.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Danaher reports 4% increase in Q2 revenues